๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Non-Small Cell Lung Cancer
Clinical trial register · India

Non-Small Cell Lung Cancer Trials in India, 2026

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1128 matching records held by the registry are in this view. Synced 24 Sep 2026, 03:16 UTC
1128
Studies in scope
all four open statuses
612
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
Mumbai 9 New Delhi 9 Kolkata 6 Nashik 6 Bengaluru 5
Narrow the registerReset
Recruitment status
Phase
Site location
Mumbai9 New Delhi9 Kolkata6 Nashik6 Bengaluru5
All 36 locations
Target enrolment
to

Non-Small Cell Lung Cancer trials in India

20 of 1128 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
NCT07565987Non Small Cell Lung Cancer
All India Institute of Medical Sciences
Not applicable
20
Jhajjar
2026-12-19
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
850
Vadodara, Badsa, Gurgaon, Belagavi, Pune, Mohali, Chennai
2026-09-30
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
1,410
Surat, Vadodara, Gurugram, Bangalore, Belagavi, Kottayam, Nagpur, Nashik
2026-01-06
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2/3
500
Ahmedabad, Gurugram, Bengaluru, Mumbai, Nagpur, New Delhi, Howrah
2025-11-05
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 3
686
Bangalore, Bhubaneswar, Howrah, Mangalore, Pune, Surat
2025-10-24
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
714
Bengaluru, Mumbai, Pune, Thane, New Delhi, Hyderabad
2025-07-23
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-18
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression โ‰ฅ 1%
NCT06561386Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
1,000
Badsa, Bengaluru, Thiruvananthapuram, Mumbai, New Delhi, Secunderabad, Varanasi, Howrah
2024-10-07
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
AstraZeneca
Phase 3
582
Bangalore, Delhi, Hyderabad, Kolkata, Mysuru, Nagpur, Nashik, New Delhi
2024-04-29
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
675
Chennai, Dwฤrka, Jaipur, Kolkata, Marg Jaipur, Nagpur, Nashik, New Delhi
2024-04-11
Active, closed
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
NCT05132075Non-Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 3
95
Jaipur, Delhi
2022-06-15
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
791
Ahmedabad, Bangalore, Delhi, Howrah, Hyderabad, Jaipur, Kolkata, Marg Jaipur
2022-02-18
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
Pfizer
Phase 4
76
Bengaluru, Thane
2021-12-28
Active, closed
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
358
Mumbai, Namakkal, New Delhi, Varanasi
2020-12-16
Active, closed
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
NCT04606771Non-Small Cell Lung Cancer
AstraZeneca
Phase 2
30
Delhi, Mumbai
2020-09-28
Active, closed
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastinยฎ in Advanced Non-squamous Non-small Cell Lung Cancer Patients
NCT03390686Lung Cancer, Non-small Cell Lung Cancer
Prestige Biopharma Limited
Phase 3
650
Nashik
2019-11-15
Recruiting
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
NCT05277844Oligometastatic Disease, Non-small Cell Lung Cancer, Driver Mutation
Tata Memorial Hospital
Phase 2
106
Mumbai
2019-11-11
Active, closed
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
587
Belagavi, Bengaluru, Gurgaon, Kolkata, New Delhi, Pune
2019-07-02
Active, closed
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
825
Ahmedabad, Gurgaon, Kolkata, Manipal, Mumbai, Mysuru, Namakkal, Nashik
2018-12-06
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-india/condition/non-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in India and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,128 studies in total at the last sync on 24 Sep 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies listing the condition Non-Small Cell Lung Cancer.

How many Non-Small Cell Lung Cancer trials are recruiting in India?

10 of the 20 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Non-Small Cell Lung Cancer), 20 studies
PhaseStudiesRecruitingShare
Phase 315875%
Phase 22110%
Not applicable105%
Phase 2/3115%
Phase 4105%

Most active sponsors

Lead sponsors with the most studies (Non-Small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca83
Bristol-Myers Squibb32
Pfizer32
All India Institute of Medical Sciences10
Daiichi Sankyo11
Merck Sharp & Dohme LLC11
Novartis Pharmaceuticals10
Prestige Biopharma Limited10
Tata Memorial Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.